Top Story Today
One Cancer Therapy. Three Autoimmune Diseases. All Gone.
A 47-year-old German woman who depended on daily blood transfusions after a decade of failed treatments had all three of her autoimmune diseases wiped out by a single CAR-T infusion. One year later, she's in treatment-free remission with no medications. When her B cells eventually regrew, they came back as naive cells with no memory of attacking her body; essentially a factory reset for her immune system. Over 100 clinical trials for CAR-T in autoimmune diseases are now underway globally, and the patient experienced only mild side effects compared to the severe reactions that plague cancer patients.
Why it matters: This case proves CAR-T's immune reset isn't limited to one disease at a time, accelerating a billion-dollar race to bring the therapy beyond oncology and into conditions like lupus, MS, and rheumatoid arthritis.
Read more →Science & Discovery
Your Gut Bacteria Might Be Giving Your Brain ALS
Case Western researchers found that toxic sugars produced by gut bacteria can trigger ALS and frontotemporal dementia by sparking immune attacks on the brain. Seventy percent of ALS/FTD patients had elevated levels of these bacterial sugars, compared to roughly a third of healthy controls. Reducing them in experimental models extended lifespans. Clinical trials targeting this gut-brain pathway could begin within a year.
Read more →The $200 Billion Molecule Nobody Has a Drug For
Analysts are calling Lp(a) inhibitors biotech's next blockbuster category. Some 65 million Americans carry elevated levels of this genetically determined cholesterol particle, and zero approved treatments exist. At least five candidates from Novartis, Lilly, and Amgen are in the race, with the first definitive outcomes trial (HORIZON) expected to report this summer.
Read more →Deals & Funding
Shanghai Biotech Bets $110M It Can Crack Solid Tumor CAR-T
Oricell Therapeutics closed a $110 million pre-IPO round to push its GPC3-targeting CAR-T therapy into pivotal trials for liver cancer. If it works, Ori-C101 would be the world's first approved CAR-T for a solid tumor. Vivo Capital, Qiming Venture Partners, and a sovereign wealth fund co-led the round.
Read more →Avalyn Pharma Files for Nasdaq IPO to Reinvent Lung Medicine
Avalyn filed its S-1 to fund inhaled therapies that deliver 35x more drug concentration to the lungs with a fraction of the side effects of oral versions. Its lead candidate targets pulmonary fibrosis, and Phase 1b data showed over 70% of patients on the higher dose saw fibrosis stabilize or improve. Morgan Stanley and Jefferies are running the books.
Read more →Industry & Policy
Biotech VCs Are Having an Identity Crisis
A STAT investigation based on interviews with two dozen VCs and LPs reveals an industry caught between AI companies siphoning investor dollars and Chinese drugmakers doing the same science at a fraction of the cost. Chinese out-licensing deals surged to roughly $137 billion in 2025, while AI-bio firms like Insilico signed $1.3 billion in new pharma deals that same year.
Read more →6,000 Women Enter Menopause Daily. Pharma Still Can't Keep Up.
Despite a market projected to reach nearly $28 billion by 2030 and record VC funding in women's health, menopause drug development keeps stumbling. Only 2 million prescriptions exist among 41 million eligible women. Broken trial designs, missing endpoints for symptoms beyond hot flashes, and the lingering shadow of a flawed 2002 study continue to hold the field back.
Read more →America's Top Health Official Uses Unproven Peptides While Questioning Vaccines
HHS Secretary RFK Jr. demands more research on vaccines (one of medicine's most studied interventions) while personally using peptides that have never passed a human clinical trial. A STAT analysis highlights the contradiction, warning it could reshape FDA regulation and undermine the principle of proving a product works before selling it.
Read more →